<p>Obesity is a known risk factor for breast cancer, so could some women reduce their odds of this common cancer by taking weight-loss drugs such as Wegovy and Zepbound? A new study presented at a major cancer conference in Chicago suggests that possibility.</p><p>The study of more than 111,000 women found that those who took popular GLP-1 drugs prescribed for obesity or diabetes had a more than 30% lower risk of breast cancer, though the researchers cautioned that the observational study doesn't prove the popular weight-loss drugs reduce cancer risk.</p><p>Still, along with research released in May that found that GLP-1 users were less likely to see some obesity-related cancers spread, <a class="Link" href="https://ascopost.com/videos/asco-2026/elizabeth-mcdonald-on-glp-1-agonists-and-breast-cancer-incidence/" target="_blank" >Dr. Elizabeth McDonald,</a> a University of Pennsylvania researcher, said her study linking breast-cancer prevention to GLP-1 drugs should "only increase the possibility there's a real biological signal" that should be studied in a robust clinical trial.</p><p>The study was presented at the recent American Society of Clinical Oncology conference at McCormick Place and published this month in the peer-reviewed medical journal JCO Oncology Practice.</p><p>Other than skin cancer, breast cancer is the most common cancer among U.S.